Accelus Secures Growth Financing to Advance Expandable Spinal Implant Technology
核心洞察
Accelus, a medical technology company specializing in expandable spinal implant technology, closed a new equity financing round led by Concord Health Partners (搜索) to support commercial expansion and pipeline development.
The company has achieved significant clinical adoption with more than 32,000 cages implanted across 25 countries using its FlareHawk and Toro-L interbody fusion systems.
Industry veteran Bernie Haffey was appointed Chairman of the Board of Directors to oversee the company's next growth phase and expansion of minimally invasive spine surgery solutions.
Accelus, a privately held medical technology company focused on expandable spinal implant technologies, announced the closing of a new equity financing round led by Concord Health Partners (搜索). The Palm Beach Gardens, Florida-based company will use the capital to support continued commercial growth and advance development of its differentiated spinal implant portfolio.
The financing comes as Accelus has demonstrated significant clinical adoption of its technologies, with more than 32,000 cages implanted across 25 countries. The company's product portfolio centers on expandable spinal implant systems designed to enhance surgical procedures and patient outcomes through minimally invasive approaches.
Leadership Appointment and Strategic Direction
In conjunction with the financing, Accelus appointed Bernie Haffey as Chairman of the Board of Directors. Haffey, who joined the board in February 2024, brings over 20 years of medtech and healthcare sector experience to the role. He founded and serves as President of Haffey&Co, a strategic business management consultancy, and previously served as President & CEO of medtech companies Nexis Vision Inc and NDO Surgical.
"The continued support from our partners through this latest equity financing round reinforces our long-term vision to bring meaningful innovation to spine care and expand access to minimally invasive solutions for both surgeons and patients," said Kevin McGann, President and CEO of Accelus. "We are now well positioned to deepen our U.S. market presence and invest in future pipeline innovations that meet the real-world needs of spine surgeons across care settings."
Product Portfolio and Technology Platform
Accelus's technology platform includes the FlareHawk Interbody Fusion System (搜索) featuring Adaptive Geometry technology, the LineSider Spinal System (搜索) with modular-cortical screws, and the Toro-L Interbody Fusion System (搜索). These differentiated implants and instruments support a wide range of minimally invasive techniques suitable for both hospital and ambulatory surgery center environments.
The company's Adaptive Geometry technologies are specifically designed for transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), endoscopic-assisted, percutaneous, and lateral spine surgeries. The systems aim to preserve patient anatomy, enhance procedural efficiency, and promote long-term spinal stability.
Market Expansion and Future Development
The additional funding will enable Accelus to expand its reach and continue building momentum as it grows its FlareHawk and Toro portfolios. The company has established what it describes as a strong foundation for growth by delivering scalable, surgeon-driven technologies that challenge traditional limitations in spine surgery.
"I am delighted to take this new role as Chairman of the Accelus Board at an important time in the Company's evolution," said Haffey. "I look forward to working with Kevin and the rest of the Accelus team to help drive continued growth and advance the Company's ongoing commitment to building on its best-in-class product offering and stellar reputation."
Concord Health Partners (搜索), the lead investor, is a healthcare-focused investment firm that focuses on investing in healthcare companies with potential to enhance the value of care through technologies and solutions that lower costs, improve quality, and expand access to care.